The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | APRIL depletion and loss of durable antibody-mediated immunity in multiple myeloma
Noé Perron, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses how tumor burden-dependent depletion of a proliferation-inducing ligand (APRIL) may contribute to the loss of durable antibody-mediated immunity in patients with multiple myeloma and precursor conditions. He highlights findings showing declining vaccine-induced antibody titers and reduced immunity to measles, mumps, and rubella, and explores the potential clinical implications for infection risk, vaccination strategies, antibody monitoring, and therapies targeting APRIL-related pathways. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
